



Deciphering the cellular response to IFN treatment in HDV-infected cells

Claudie Eber^{1,*}, Roxanne Fouillé^{2,*}, Emma Gerges¹, Zoé Lebrun¹, David Durantel², Thomas F. Baumert¹, Julie Lucifora^{2,\$}, Eloi R. Verrier^{1,\$}

1 University of Strasbourg, Inserm, Institute for Translational Medicine and Liver Disease (ITM), UMR_S1110, Strasbourg; 2 CIRI, Centre International de Recherche en Infectiologie, Univ Lyon, Inserm, U1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, ENS de Lyon, F-69007, Lyon, France; 3 Institut hospitalo-universitaire (IHU). Service d'hépato-gastroentérologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France; 4 Institut Universitaire de France (IUF), Paris, France.

*These authors contributed equally \$These authors contributed equally

Introduction

- O Hepatitis delta virus (HDV) induces an endogenous interferon (IFN) response through the recognition of its ribonucleoprotein by MDA5 and LGP2.
- O HDV detection by the cellular sensors leads to the production of IFN-α and IFN-λ which activate the JAK/STAT signaling pathway and induce the expression of interferon-stimulated genes (ISGs), some of them exhibiting antiviral propreties.
- ISG expression is also triggered by the exogenous treatment with IFN-a or IFN-λ.
- O Intrestingly, HDV replication is moderatly affected by both endogenous and exogenous IFN-a *in vivo* and *in vitro*.
- Furthermore, it has been shown that the ability of IFN-a to trigger ISGs expression is impaired in HDV infected cells^{1,2}.
- O The aim of our study is to understand the molecular mechanisms of this inhibition.

Figure 1: Is The IFN response inhibited by HDV proteins or by an negative feedback loop of the JAK/STAT pathway? IFN-λ IFNAR2 IFNAR1 IFNLR1 IL-10R2 (TYK2) JAK1 TYK2 STAT2 STAT1 RIG-I STAT2 IFN STAT1 STAT2 → IFN gene STAT


Methods

- O We analyzed the transcriptomic impact of IFN-α and IFN-λ on both HDV- and mock- infected dHepaRG cells by RNAseq.
- O To evaluate the role of HDV antigens in the interaction with IFN signaling, we overexpressed S-HDAg and L-HDAg by AAV-meditated transduction in dHepaRG cells.
- O To assess the impact of the innate immune response, we took advantage of dHepaRG cells KO for RIG-I or MDA5, exhibiting a differential response to HDV infection (Table 1). Cells were infected with HDV for six days followed by treatment with either IFN-α (500 IU/mI) or IFN-λ-1 (IL-29, 100 ng/mI).

	IFN production after HDV infection		IFN response after cell treatment	
	YES	NO	YES	NO
dHepaRG	X		X	
dHepaRG RIG-I _{KO}	X		X	
dHepaRG MDA5 _{KO}		X	x	


Results

HDV INFECTION SPECIFICALLY DISRUPTS THE IFN-a RESPONSE




O The cellular response to IFN-α, but not IFN-λ, is impaired in HDV-infected dHepaRG cells.

EXPRESSION OF HDV PROTEINS DOES NOT INTERFERE WITH THE IFN RESPONSE



O HDV antigens expression has no impact on IFN-a-induced ISG expression

HDV-INDUCED PREACTIVATION OF IFN RESPONSE IS RESPONSIBLE FOR ITS INHIBITION



- The IFN-a response is no longer inhibited in absence of HDV sensing in dHepaRG-MDA5_{KO} cells.
- O This suggests that the preactivation of the innate immune response induced by HDV infection specifically inhibits the response to IFN-a.

Hypothesis


USP18 IS A KEY INHIBITOR OF THE IFN-a RESPONSE

- USP18 (ubiquitin specific peptidase) is an ISG known to be involved in ISGylation mediated by ISG15.
- This protein was identified as a major inhibitor of the IFN-a mediated response through its association with the IFNAR2 subunit, leading to the displacement of JAK1³.
- According to RNA-seq data, USP18 is upregulated in HDV infected cells.
- O This protein may be involved in the inihibtion of the IFN-a response by HDV.

IFN-q IFN-q IFN-A IFNAR2 IFNAR1 IFNLR1 I

Results

USP18 MODULATE THE TYPE I BUT NOT TYPE III IFN RESPONSE IN HDV-INFECTED CELLS



 Partial restauration of ISG induction upon IFN treatment in USP18 knockdown cells

Conclusion/Perspectives

- The HDV-induced IFN response following HDV infection inhibits the response to IFN-a, but not IFN-λ treatment.
- O This innate immune response induces a negative feedback loop which in turn inhibits the activation of STAT proteins.
- The ISG USP18 contributes to this negative feedback loop.
- The partial restauration upon USP18 knockdown raises the question of an alternative mechanism of action that could be involded.

References